Metrics as of 10/17/2026, 08:41 AM (Berlin time), refresh in progress.
X4 Pharmaceuticals Stock
X4 Pharmaceuticals, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Adam R. Craig
- Employees
- 45
- Market cap
- $257 M
- IPO
- 16/11/2017
X4 Pharmaceuticals, Inc. is a biopharmaceutical firm committed to the discovery, development, and commercialization of innovative therapies for uncommon immune system disorders. Its primary drug candidate, XOLREMDI (also known as mavorixafor), is an orally administered, small-molecule antagonist specifically designed…
X4 Pharmaceuticals stock: price history
1D
-1.9%
1W
-11.0%
1M
-26.2%
6M
-39.6%
YTD
-35.3%
1Y
-12.8%
2Y
-83.8%
5Y
-98.3%
10Y
–
Next earnings date
Next earnings date
04/11/2026 (in 18 days)
Volatility around earnings
~48% stronger price swings than usual
Ask the agents about X4 Pharmaceuticals
Analyst assessment of X4 Pharmaceuticals
PRICE TARGET LOW
US$11.00
CONSENSUS
US$11.50
MEDIAN
US$11.50
PRICE TARGET HIGH
US$12.00
0
STRONG BUY
12
BUY
1
HOLD
0
SELL
0
STRONG SELL
13
TOTAL · Buy
As of: 05/12/2025
X4 Pharmaceuticals stock metrics
P/E
-2.16
P/B
2.11
EV/EBITDA
-1.74
RETURN ON EQUITY
-10.4%
NET MARGIN
-183.5%
DEBT/EQUITY
0.5
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
57.7%
FLOAT SHARES
57,226,509
AVG. DAILY VOLUME (30D)
1,080,795
Insider transactions (SEC)
KIRSKE DAVID
Craig Adam R
Volpone John
KIRSKE DAVID
KIRSKE DAVID
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about X4 Pharmaceuticals stock
What does X4 Pharmaceuticals do?
X4 Pharmaceuticals, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Adam R. Craig, the company employs around 45 people.
The IPO was on 16/11/2017; the stock trades on NASDAQ under the ticker XFOR.
What do analysts say about X4 Pharmaceuticals stock?
13 analysts rate the stock, the consensus is Buy (as of 05/12/2025).
The average price target is US$11.50, ranging from US$11.00 to US$12.00, with a median of US$11.50.
This is an external assessment, not a statement by Market Jury.
When does X4 Pharmaceuticals report next?
The next earnings date is 04/11/2026.
Around past earnings, price swings were roughly 48% stronger than usual.
Does X4 Pharmaceuticals pay a dividend?
No, X4 Pharmaceuticals currently does not pay a dividend.
Which stocks are comparable to X4 Pharmaceuticals?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get X4 Pharmaceuticals stock analyzed?
Clicking "Analyze stock" lets five strategies assess X4 Pharmaceuticals against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.